3 results about "Hypercoagulable states" patented technology

Viscoelastic coagulation monitoring systems having two glass discs mounted on flexible plastic arms for receiving a sample of blood therebetween, and an analyzer configured to measure a coagulation response of the sample of blood to determine whether the sample of blood indicates a hypercoagulable state in a HS patient are provided. The system may cause movement of a first glass disc relative to a second glass disc at a sufficient speed to cause coagulation of the sample of blood, and the analyzer may measure various parameters of the coagulation response including, e.g., Clotting Time (CT), Clot Formation Time (CFT), Alpha Angle (a-angle), Maximum Clot Firmness (MCF), Amplitude at 10 and 20 minutes (A10, A20, respectively), Lysis Index at 30 and 45 minutes (LI30 and LI45, respectively), indicative of a hypercoagulable state in a HS patient.

The present invention covers the use of chymase inhibitors in general and more in particular substituted bicyclically substituted uracils of general formula (I) as described and defined herein, and 3-methylbenzo-[b]thiophene)-2-sulfonamido derivatives of general formula (II) for manufacturing pharmaceutical compositions for the treatment or prophylaxis of stroke, pulmonary embolism, deep or superficial vein thrombosis, thrombotic microangiopathy, thrombotic microangiopathy in hypercoagulable states after infection, inflammation, transplantation, disseminated intravascular coagulation, vaccine-induced immune thrombotic thrombocytopenia, vascular access site thrombosis or occlusion.

The invention discloses application of ubiquitination modification of protein in rheumatism related to cell inflammatory response and hypercoagulable state, and belongs to the technical field of rheumatism molecular biology. Ubiquitin-binding enzyme UBE2A is highly expressed in RA patients, and an NF-kappa B signal channel is activated by mediating ubiquitination modification of NEMO, so that inflammatory response and hypercoagulable state are promoted. Bioinformatics analysis, machine learning screening, a cell co-culture model and clinical sample verification are comprehensively utilized to prove that UBE2A is a key molecule in the RA pathogenesis process, and it is prompted that UBE2A can be used as a new target for RA diagnosis / treatment. Therefore, UBE2A and related pathways thereof can be used for preparing medicines for treating rheumatoid arthritis, especially for regulating inflammation and abnormal blood coagulation.